XEN Glaucoma Implant for the Management of Operated Uncontrolled Glaucoma: Results and Complications during a Long-Term Follow-Up

This study aimed to analyze the surgical and refractive outcomes of XEN glaucoma implant (Allergan, an Abbvie company, Irvine, CA, USA), a minimally invasive surgical device for the treatment of operated uncontrolled glaucoma. Eyes that received XEN Gel Stent placement from December 2014 to October...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:J Ophthalmol
Prif Awduron: Lewczuk, Katarzyna, Konopińska, Joanna, Jabłońska, Joanna, Rudowicz, Jacek, Laszewicz, Patrycja, Mariak, Zofia, Rękas, Marek
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Hindawi 2021
Pynciau:
Research Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC8285170/
https://ncbi.nlm.nih.gov/pubmed/34306742
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2021/2321922
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg